Boehringer Ingelheim Ditches Phase II Alzheimer's Program Post author:Sam Post published:February 8, 2018 Post category:BioPharma Another potential treatment for Alzheimer’s disease has been tossed into the rubbish bin. Source: BioSpace You Might Also Like Indiana University School of Medicine Awarded Prestigious $2.1 Million Grant To Study Traumatic Brain Injury October 1, 2017 Valeant Board Of Directors Issues Statement On s Cooperation With Senate Committee On Aging April 11, 2016 Serial Investor Takes Stake in Bristol-Myers Squibb, Stock Jumps February 21, 2017
Indiana University School of Medicine Awarded Prestigious $2.1 Million Grant To Study Traumatic Brain Injury October 1, 2017
Valeant Board Of Directors Issues Statement On s Cooperation With Senate Committee On Aging April 11, 2016